TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9972993

Group type: EXPERIMENTAL
Intervention: SLAM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLEDAI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BILAG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECLAM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLICC/ACR Damage Index (SDI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-20
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 0
Study: 7564341

Group type: EXPERIMENTAL
Intervention: mexiletine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: aprindine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: disopyramide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: pilsicainide
Number of subjects: 16
Study: 1907840

Group type: EXPERIMENTAL
Intervention: Oral lithium carbonate (500 mg)
Number of subjects: 6
Study: 6778757

Group type: EXPERIMENTAL
Intervention: hypertonic glucose alone (49.2 +/- 7.9 kcal/kg day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: intravenous fat emulsion (60% of the nonprotein energy) in addition to hypertonic glucose (51.5 +/- 5.0 kcal/kg/day)
Number of subjects: 16
Study: 31820604

Group type: EXPERIMENTAL
Intervention: Acupoint stimulation (auricular point pressing with magnetic beads and transcutaneous electrical acupoint stimulation at bilateral Hegu and Neiguan)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acupoint stimulation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (medical adhesive plaster with no stimulation)
Number of subjects: 62
Study: 28561216

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention consisting of 5 sessions covering topics such as disclosure of diagnosis and legal frameworks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received treatment as usual.
Number of subjects: 0
Study: 27474496

Group type: EXPERIMENTAL
Intervention: Treatment group (videotapes of EOL and ED encounters)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Online course usage
Number of subjects: 72
Study: 24684103

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with general anesthesia (GA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 160
Study: 22909343

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg after each haemodialysis session
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gabapentin and Pregabalin
Number of subjects: 50
Study: 19732370

Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 221
Study: 17566639

Group type: EXPERIMENTAL
Intervention: TmLRP‐TT
Number of subjects: 100

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TmLRP‐TT and TURP
Number of subjects: 100
Study: 15956789

Group type: EXPERIMENTAL
Intervention: Modified allergen vaccine (maximum concentration 990 mug/ml, 100 times the maximum dose of native extract)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Unmodified allergen extract (maximum concentration 70 mug/ml, potency 10 HEP(L)/ml)
Number of subjects: 35
Study: 12527147

Group type: EXPERIMENTAL
Intervention: 12-week intervention based on stages of change
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 316
Study: 10802462

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 50
Study: 9148259

Group type: EXPERIMENTAL
Intervention: Nd:YAG capsulotomy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intact posterior capsule
Number of subjects: 75
Study: 1517787

Group type: EXPERIMENTAL
Intervention: 4‐epi‐doxorubicin plus cisplatin
Number of subjects: 157

Group type: COMPARATOR
Intervention: 4‐epi‐doxorubicin alone
Number of subjects: 157
Study: 6206578

Group type: EXPERIMENTAL
Intervention: Radiation with bleomycin or vinblastine or a combination of both
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Larger radiation fraction and shorter treatment time schedule
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Radiation with chemotherapy
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Monochemotherapy
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Pharyngostomy tube
Number of subjects: 272
Study: 30545282

Group type: EXPERIMENTAL
Intervention: Telehealth Education Program (TEP)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 107
Study: 28505227

Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg/d) with exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 30
Study: 26868063

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous iron sucrose (ISC)
Number of subjects: 60
Study: 25017619

Group type: EXPERIMENTAL
Intervention: Schizophrenia (SZ) patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bipolar disorder (BD) patients
Number of subjects: 60
Study: 23008078

Group type: EXPERIMENTAL
Intervention: Didactic lecture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lecture plus case discussion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lecture plus small-group training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study: 19608703

Group type: EXPERIMENTAL
Intervention: Bicarbonate supplementation
Number of subjects: 134
Study: 17241249

Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg three times a day for 3 days
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 15458569

Group type: EXPERIMENTAL
Intervention: Metadate CD 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metadate CD 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concerta 18 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concerta 36 mg
Number of subjects: 0
Study: 10703815

Group type: EXPERIMENTAL
Intervention: Therapeutic monoclonal antibodies (mAb)
Number of subjects: 0
Study: 8894485

Group type: EXPERIMENTAL
Intervention: Baseline proinsulin levels
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Baseline fasting glucose levels
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Baseline 2-h glucose levels
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Baseline fasting C-peptide levels
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Baseline intra-abdominal fat area
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Disproportionate hyperproinsulinaemia
Number of subjects: 87
Study: 1565535

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3935343

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verapamil (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29289554

Group type: EXPERIMENTAL
Intervention: 0.5 mg Testosterone + 50 mg Sildenafil
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: 0.5 mg Testosterone + 10 mg Buspirone
Number of subjects: 497
Study: 26569055

Group type: EXPERIMENTAL
Intervention: Laparoscopic nerve-sparing radical hysterectomy (LNSRH)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Laparoscopic radical hysterectomy (LRH)
Number of subjects: 106
Study: 23558873

Group type: EXPERIMENTAL
Intervention: Mifepristone 1200 mg every 12 hours with a high-fat meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20388644

Group type: EXPERIMENTAL
Intervention: Active guideline implementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18004577

Group type: EXPERIMENTAL
Intervention: Navigated implantation technique
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional implantation technique
Number of subjects: 64
Study: 15713143

Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibodies (IgG, IgA, IgM) measured using a solid‐phase enzyme immunoassay
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibodies (IgA, IgM)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibodies
Number of subjects: 91
Study: 12522361

Group type: EXPERIMENTAL
Intervention: Endotracheal tube introducer (ETTI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard orotracheal intubation (SOTI)
Number of subjects: 51
Study: 10711877

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 9
Study: 8610795

Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate 0.25%
Number of subjects: 371

Group type: COMPARATOR
Intervention: Timolol maleate 0.25%
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate 0.5%
Number of subjects: 371

Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate (0.25% and 0.5%)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Timolol maleate (0.25% and 0.5%)
Number of subjects: 371
Study: 1477848

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg single oral dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Propranolol (120 mg daily for 2 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Propranolol (240 mg daily for 2 weeks)
Number of subjects: 9
Study: 3982837

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (mock TNS)
Number of subjects: 48
Study: 31364209

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management (CDSM) program
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 420
Study: 27759614

Group type: EXPERIMENTAL
Intervention: Magnetic surgical system (Levita Magnetics' Surgical System) used during a 3-port laparoscopic technique
Number of subjects: 50
Study: 27787387

Group type: EXPERIMENTAL
Intervention: Saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 69
Study: 24804913

Group type: EXPERIMENTAL
Intervention: Structured ward round training (Intervention Group, IG; n=18) during an eight-week training course.
Number of subjects: 36

Group type: COMPARATOR
Intervention: On-ward training regarding how to take patient histories and perform physical examinations (Control Group, CG; n=18).
Number of subjects: 36
Study: 22563952

Group type: COMPARATOR
Intervention: Acamprosate treatment
Number of subjects: 0
Study: 20132142

Group type: EXPERIMENTAL
Intervention: Melbourne Assessment of Unilateral Upper Limb Function (MUUL)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Assisting Hand Assessment (AHA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stereognosis
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sensory measures
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison with typically developing children
Number of subjects: 70
Study: 17945260

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP) pulses (1 g/day for 5 days with an oral prednisone taper, every 4 months for 3 years, then every 6 months for 2 years)
Number of subjects: 88

Group type: COMPARATOR
Intervention: IVMP only for relapses (1 g/day for 5 days with an oral prednisone taper)
Number of subjects: 88
Study: 19390550

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study: 15063963

Group type: EXPERIMENTAL
Intervention: Metformin plus Clomiphene Citrate (CC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) alone
Number of subjects: 21
Study: 11343406

Group type: EXPERIMENTAL
Intervention: Integration of facial features in adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted salience of facial features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted Fuzzy Logical Model of Perception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Developmental differences in face identification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information used for face identification
Number of subjects: 0
Study: 9222709

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily and clarithromycin 500 mg b.i.d. (PC)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily, clarithromycin 500 mg b.i.d. plus amoxicillin 1 g b.i.d. (PCA)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate 120 mg t.i.d., roxithromycin 150 mg b.i.d., metronidazole 250 mg b.i.d. plus ranitidin 300 mg (BRMR)
Number of subjects: 250
Study: 8236398

Group type: EXPERIMENTAL
Intervention: Intramuscular quinine (20 mg/kg followed by 10 mg/kg every 8 h)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intravenous quinine (20 mg/kg followed by 10 mg/kg every 8 h)
Number of subjects: 104
Study: 3522030

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aluminum ibuprofen 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11777644

Group type: EXPERIMENTAL
Intervention: Simultaneous Integrated Boost (SIB) technique
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sequential Boost technique
Number of subjects: 5
Study: 31368135

Group type: EXPERIMENTAL
Intervention: Clinical pathway group (electronic clinical pathway management)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (routine blood glucose control treatment)
Number of subjects: 264
Study: 30451141

Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 515

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 515
Study: 27456299

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing dressings
Number of subjects: 613

Group type: COMPARATOR
Intervention: Non-chlorhexidine control dressings
Number of subjects: 613
Study: 24552795

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) applied for 1 randomly assigned leg after each training session, consisting of 3 4-minute intervals with a 30-second rest period
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control leg (not cooled)
Number of subjects: 17
Study: 23061606

Group type: EXPERIMENTAL
Intervention: Intensive facial exercises for 5 minutes after the first and third botulinum toxin-A treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rest in a seated position for 5 minutes after the second treatment (control group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Squeezing exercises after the second treatment (Group B)
Number of subjects: 26
Study: 20305329

Group type: EXPERIMENTAL
Intervention: Clebopride
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 18520606

Group type: EXPERIMENTAL
Intervention: 400 mg dose of norfloxacin (test formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 mg dose of norfloxacin (reference formulation)
Number of subjects: 0
Study: 15823282

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12391117

Group type: COMPARATOR
Intervention: Albuterol (inhaled bronchodilator)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Salmeterol (3-week treatment)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10529079

Group type: EXPERIMENTAL
Intervention: Intracoronary lacidipine (12 microg, 3 repeated boluses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intracoronary papaverine (10 mg)
Number of subjects: 8
Study: 7745509

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 385

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 385
Study: 1971644

Group type: EXPERIMENTAL
Intervention: Empirical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologicals
Number of subjects: 0
Study: 7437378

Group type: EXPERIMENTAL
Intervention: Complete rest in bed
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ambulation (allowed to move freely in the ward)
Number of subjects: 40
Study: 30117241

Group type: EXPERIMENTAL
Intervention: Teachers encouraging children to obtain glasses
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Teachers supporting children's classroom glasses wear
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Teachers believing glasses harm children's vision
Number of subjects: 882
Study: 28707379

Group type: EXPERIMENTAL
Intervention: Angiolite drug-eluting stent (DES)
Number of subjects: 103
Study: 27234640

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 472

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 472
Study: 24647459

Group type: EXPERIMENTAL
Intervention: Moderate glycemic index energy (MGI) bar (47.3 g CHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fasting (water)
Number of subjects: 10
Study: 22529095

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Locking-plate fixation
Number of subjects: 24
Study: 20021294

Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral rivastigmine
Number of subjects: 0
Study: 17666359

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 109

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 109
Study: 15911704

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 30 mg orally
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 12913835

Group type: EXPERIMENTAL
Intervention: High-titer (HT) Edmonston-Zagreb measles vaccine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard-titer (ST) measles vaccine
Number of subjects: 9
Study: 10919683

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg via HFA 134a pMDI
Number of subjects: 380

Group type: COMPARATOR
Intervention: Fluticasone propionate 250 microg via CFC pMDI
Number of subjects: 380
Study: 8820174

Group type: EXPERIMENTAL
Intervention: Yohimbine HCl (16 mg po) administered 30 min before clonidine (2 ug/kg infused over 10 min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Yohimbine HCl (16 mg po) administered 30 min before apomorphine (0.5 mg sc)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clonidine (2 ug/kg infused over 10 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Apomorphine (0.5 mg sc)
Number of subjects: 15
Study: 1445740

Group type: COMPARATOR
Intervention: 12 week chemotherapy regimen
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 36 week chemotherapy regimen
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Amenorrheic patients
Number of subjects: 114

Group type: COMPARATOR
Intervention: Non-amenorrheic patients
Number of subjects: 114
Study: 6538423

Group type: EXPERIMENTAL
Intervention: Antibiotics plus nimesulide 200 mg/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 40
Study: 30638067

Group type: EXPERIMENTAL
Intervention: ECHO-AS cohort
Number of subjects: 854493

Group type: COMPARATOR
Intervention: no-ECHO cohort
Number of subjects: 854493
Study: 29678780

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Nonresponders with nonischemic cardiomyopathy
Number of subjects: 107
Study: 27455354

Group type: EXPERIMENTAL
Intervention: Low Quality of Life (QoL) at week 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal Quality of Life (QoL) at week 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal Quality of Life (QoL) at week 4 (adjusted for baseline variables)
Number of subjects: 0
Study: 25302762

Group type: EXPERIMENTAL
Intervention: Schema-therapy
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Treatment-as-usual
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Clarification-oriented psychotherapy
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Patients with co-occurring depression
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 320
Study: 22550699

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 17802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study: 20496307

Group type: EXPERIMENTAL
Intervention: Kanamycin POS® eye ointment (5 times a day for 7 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo eye ointment
Number of subjects: 25
Study: 18568983

Group type: EXPERIMENTAL
Intervention: Short lag
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long lag
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elderly controls
Number of subjects: 0
Study: 16098854

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR) 12.5 mg
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR) 25 mg
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 11903942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 20 microg x kg(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg x kg(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 80 microg x kg(‐1)
Number of subjects: 100
Study: 9685028

Group type: EXPERIMENTAL
Intervention: Nipple cone morphology
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Oval cone morphology
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Aetiological factors
Number of subjects: 89
Study: 7972349

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24